Reviewer's report

Title: Metabotropic glutamate receptor 5: a candidate in psychiatric pathology? Implications for future mGluR5-based therapeutics

Version: 1 Date: 1 December 2013

Reviewer: Abraham AW Weizman

Reviewer's report:

This is a well-written short review on the pharmacological role of mGluR5 in psychiatric disorders. The authors relate mainly to its possible involvement in schizophrenia and depression. They describe the interaction between mGluR5 and NMDAR and the effect of mGluR5 on glutamatergic neurotransmission. The major advantage of this article is its conciseness and clearness.

Minor Essential Revisions

This reviewer suggests

1. To add a paragraph on pharmacological trials on the effect of mGluR5 ligands in animal models of schizophrenia and major depression,
2. To add a short paragraph on the possible role of mGluR5 in anxiety disorders and autism spectrum disorders, at least at the level of animal models and pre-clinical data,
3. The authors could use the review by Krivoy A, Fischel T, Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur Neuropsychopharmacol. 2008;18:395-405, to show the interaction between the mGlu receptors and their relevance to psychopathology.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No conflict of interest to declare in relation to this study.